Carboplatin-Induced Kounis Syndrome

Tambe, Vikrant; Tambe, Ajay; Goodman, Alexandra; Shepherd, Zachary

doi:10.1097/mjt.0000000000001027

Cited by 5 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a meta-analysis published by Raschi et al in 2018, drugs were responsible for KS in 142 publication compared with other causes out of a total of 252 reviewed articles [ 10 ]. The most frequently implicated drugs are NSAIDs [ 11 , 12 ], followed by antibiotics [ 13 ], antineoplastic drugs [ 14 ], contrast media [ 15 ], corticosteroids [ 16 ], and proton pump inhibitors [ 17 ], among others.…”

Section: Etiology and Epidemiologymentioning

confidence: 99%

Drug-Induced Kounis Syndrome: Latest Novelties

Ollo-Morales,

Gutierrez-Niso,

De-la-Viuda-Camino

et al. 2023

Curr Treat Options Allergy

View full text Add to dashboard Cite

Opinion statement Kounis syndrome (KS) is defined by an acute coronary syndrome associated with hypersensitivity reactions, an under-diagnosed life-threatening medical emergency. Although multiple causes have been described, drugs constitute the most frequent cause. The purpose of this review is to update knowledge about drug-induced KS, to give guidelines on the correct diagnosis and treatment. This article reviews the literature on drug-induced KS from the last 5 years. Antibiotics and NSAIDs are the most frequently implicated drugs. In addition, data on pathophysiology, clinical presentation, diagnosis, and management are reviewed in detail. Highlight that there is a great deal of variability in the diagnosis and especially in the treatment of KS. This review provides a valuable selection of practical resources for all stakeholders to support effective care for KS, from a cardiologic and allergologic point of view. Future research should focus on developing validated, evidence-based, and patient-centered tools to improve the management of KS.

show abstract

Section: Etiology and Epidemiologymentioning

confidence: 99%

Drug-Induced Kounis Syndrome: Latest Novelties

Ollo-Morales,

Gutierrez-Niso,

De-la-Viuda-Camino

et al. 2023

Curr Treat Options Allergy

View full text Add to dashboard Cite

show abstract

“…Severe cardiac hypersensitivity reactions, such as the acute hypersensitivity-induced Kounis-type myocardial infarction, can occur in response to platinum agents and manifest as the usual symptoms of IgE/mast cell-mediated hypersensitivity reactions [ 20 , 21 , 22 , 23 , 24 , 25 ].…”

Section: Hypersensitivity To Cytotoxic Agents and Kounis Syndromementioning

confidence: 99%

Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome

Kounis,

Hung,

de Gregorio

et al. 2024

Life

View full text Add to dashboard Cite

Cancer therapy can result in acute cardiac events, such as coronary artery spasm, acute myocardial infarction, thromboembolism, myocarditis, bradycardia, tachyarrhythmias, atrio-ventricular blocks, QT prolongation, torsades de pointes, pericardial effusion, and hypotension, as well as chronic conditions, such as hypertension, and systolic and diastolic left ventricular dysfunction presenting clinically as heart failure or cardiomyopathy. In cardio-oncology, when referring to cardiac toxicity and cardiovascular hypersensitivity, there is a great deal of misunderstanding. When a dose-related cardiovascular side effect continues even after the causative medication is stopped, it is referred to as a cardiotoxicity. A fibrotic response is the ultimate outcome of cardiac toxicity, which is defined as a dose-related cardiovascular adverse impact that lasts even after the causative treatment is stopped. Cardiotoxicity can occur after a single or brief exposure. On the other hand, the term cardiac or cardiovascular hypersensitivity describes an inflammatory reaction that is not dose-dependent, can occur at any point during therapy, even at very low medication dosages, and can present as Kounis syndrome. It may also be accompanied by anti-drug antibodies and tryptase levels. In this comprehensive review, we present the current views on cardiac toxicity and cardiovascular hypersensitivity, together with the reviewed cardiac literature on the chemotherapeutic agents inducing hypersensitivity reactions. Cardiac hypersensitivity seems to be the pathophysiologic basis of coronary artery spasm, acute coronary syndromes such as Kounis syndrome, and myocarditis caused by cancer therapy.

show abstract

“…Severe cardiac hypersensitivity reactions, such as acute hypersensitivity-induced Kounis-type myocardial infarction, can occur in response to platinum agents and manifest as the usual symptoms of IgE/mast cell-mediated hypersensitivity reactions [32][33][34][35][36][37].…”

Section: Hypersensitivity To Cytotoxic Agents and The Kounis Syndromementioning

confidence: 99%

Cardio-Oncology: Cardiac Toxicity, Cardiovascular Hypersensitivity and Kounis Syndrome

Kounis,

Hung,

De Gregorio

et al. 2024

Preprint

View full text Add to dashboard Cite

The most frequent cause of cardiac failure globally is ischemic heart disease, with chemothera-py-related cardiovascular side effects emerging as the second most frequent cause. Cancer therapy can result in acute cardiac events, such as coronary artery spasm, acute myocardial infarction, thromboembolism, myocarditis, bradycardia, tachyarrhythmias, atrio-ventricular blocks, QT pro-longation, torsades de pointes, pericardial effusion and hypotension, as well as chronic conditions, such as hypertension, systolic and diastolic left ventricular dysfunction presenting clinically as heart failure or cardiomyopathy. In cardio-oncology, when referring to cardiac toxicity and cardiovas-cular hypersensitivity, there is a great deal of misunderstanding. When a dose-related cardiovas-cular side effect continues even after the causative medication is stopped, it is referred to as cardi-otoxicity. A fibrotic response is the ultimate outcome of cardiac toxicity, which is defined as a dose-related cardiovascular adverse impact that lasts even after the causative treatment is stopped. Cardiotoxicity can occur after a single or brief exposure. On the other hand, the term cardiac or cardiovascular hypersensitivity describes an inflammatory reaction that is not dose-dependent, can occur at any point during therapy, even with very low medication dosages, and can show up as Kounis syndrome. It may also be accompanied by anti-drug antibodies and tryptase levels. In this comprehensive review, we present the current views on cardiac toxicity and cardiovascular hypersensitivity, together with the reviewed cardiac literature on the chemotherapeutic agents inducing hypersensitivity reactions. Cardiac hypersensitivity seems to be the pathophysiologic basis of coronary artery spasm, acute coronary syndromes such as Kounis syndrome and myocardi-tis caused by cancer therapy.

show abstract

Carboplatin-Induced Kounis Syndrome

Cited by 5 publications

References 26 publications

Drug-Induced Kounis Syndrome: Latest Novelties

Drug-Induced Kounis Syndrome: Latest Novelties

Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome

Cardio-Oncology: Cardiac Toxicity, Cardiovascular Hypersensitivity and Kounis Syndrome

Contact Info

Product

Resources

About